Plasminogen Activator Inhibitor-1 Dynamics in Cardiovascular Health

Plasminogen activator inhibitor-1 (PAI-1) is the principal regulator of the fibrinolytic system, acting as the chief inhibitor of tissue-type and urokinase-type plasminogen activators. By modulating the conversion of plasminogen to plasmin, PAI-1 exerts tight control over clot dissolution, vascular remodelling and wound healing. Dysregulated PAI-1 expression or stability contributes to a spectrum of cardiovascular pathologies, from acute thrombosis to chronic atherosclerosis and tissue fibrosis. Its unique conformational plasticity underpins both physiological latency conversion and challenges in therapeutic targeting. Recent advances have elucidated structural determinants of PAI-1 function, revealed novel modulators that shift its equilibrium toward inactive forms and demonstrated the clinical potential of selectively neutralising PAI-1 to restore balanced fibrinolysis. Integrating insights from molecular crystallography to in vivo models has established PAI-1 as a biomarker of cardiovascular risk and a promising target for next-generation antithrombotic and antifibrotic therapies.

Research from Nature Portfolio

Recent studies have shown the feasibility of a fully human monoclonal antibody that binds exclusively to the active conformation of PAI-1, sterically blocking its interaction with serine proteases while preserving cofactor binding to vitronectin. High-resolution structural analysis revealed direct engagement of the reactive centre loop, offering unprecedented selectivity. In preclinical thrombosis models this antibody restored plasmin generation, limited fibrin accumulation and accelerated vascular repair without impairing vitronectin-mediated cell adhesion. This work establishes targeted immunomodulation of PAI-1 as a viable strategy for fine-tuning fibrinolytic balance in cardiovascular disease.

Plasminogen Activator Inhibitor-1 Dynamics in Cardiovascular Health publication trend

The graph below shows the total number of articles in plasminogen activator inhibitor-1 dynamics in cardiovascular health across all publications each year (not limited to Nature Index journals).

Technical terms

Plasminogen activator inhibitor-1 (PAI-1): A serine protease inhibitor that regulates fibrinolysis by blocking tissue and urokinase plasminogen activators.

Fibrinolysis: The enzymatic process by which fibrin clots are degraded to restore normal blood flow.

Reactive centre loop (RCL): A flexible peptide segment in PAI-1 critical for protease recognition and inhibitory complex formation.

Vitronectin: A glycoprotein cofactor that binds PAI-1, stabilising its active form and modulating cell adhesion.

Latency transition: The spontaneous or induced conversion of PAI-1 from an active inhibitor to an inactive, latent conformation.

Allosteric site: A region of PAI-1 distinct from the active loop that, when bound by small molecules, influences its conformational equilibrium.

References

1. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. Frontiers in Cardiovascular Medicine (2020).
2. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?. International Journal of Molecular Sciences (2021).
3. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. Scientific Reports (2019).
4. Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484. International Journal of Molecular Sciences (2021).
5. Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1*. Journal of Biological Chemistry (2010).
6. Functional Stability of Plasminogen Activator Inhibitor‐1. The Scientific World JOURNAL (2014).